XML 29 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborations and Other Arrangements (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue $ 5,859.8 $ 5,092.2  
Contract liabilities 307.8   $ 264.6
U.S.      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 3,328.8 2,890.8  
Europe      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 1,061.0 900.3  
Japan      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 592.3 543.7  
Trajenta      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 93.2 131.9  
Trajenta | U.S.      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 28.7 47.4  
Jardiance      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 267.5 203.6  
Jardiance | U.S.      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 144.6 125.2  
Basaglar      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 303.7 251.4  
Basaglar | U.S.      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 230.4 198.2  
Olumiant®      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 139.7 82.1  
Olumiant® | U.S.      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue 11.3 $ 6.4  
Lebrikizumab      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Contract liabilities 43.8    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 446.4    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 289.0    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized (250.0)    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Olumiant®      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized $ 180.0    
Royalty Agreement Terms | Olumiant®      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative arrangement, rights and obligations, percentage 20.00%    
Milestone Payments, Development and Regulatory | Olumiant®      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized $ 130.0    
Milestone Payments, Development and Regulatory | Tanezumab      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 350.0    
Milestone Payments, Development and Regulatory | Lebrikizumab      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 85.0    
Milestone Payments, Sales-based | Olumiant®      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 150.0    
Milestone Payments, Sales-based | Tanezumab      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 1,230.0    
Milestone Payments, Sales-based | Lebrikizumab      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 1,250.0    
Roche | Milestone Payments, Development and Regulatory | Lebrikizumab      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized 180.0    
Roche | Milestone Payments, Sales-based | Lebrikizumab      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestones (deferred) capitalized $ 1,030.0